ARA-290 is a research compound. It is not approved by the FDA or any regulatory body for human use. This article is for educational and informational purposes only. Nothing here constitutes medical advice. Consult a qualified physician before considering any peptide use.
ARA-290 (Erythropoietin-derived tissue-protective peptide) is a Innate repair receptor agonist, anti-inflammatory peptide researched for neuropathic pain relief, inflammation reduction, nerve fiber regeneration, improved autonomic function, metabolic control in diabetes. Common dosages range from 2-4 mg daily administered once daily. Below are the most frequently asked questions.
Frequently Asked Questions About ARA-290
What is ARA-290?
ARA-290 (Erythropoietin-derived tissue-protective peptide) is a Innate repair receptor agonist, anti-inflammatory peptide. Synthetic 11-amino acid peptide engineered from the tissue-protective domain of erythropoietin (EPO). It is researched for neuropathic pain relief, inflammation reduction, nerve fiber regeneration, improved autonomic function, metabolic control in diabetes.
What is the recommended ARA-290 dosage?
Common dosages range from 2-4 mg daily, administered once daily via subcutaneous injection. Cycles typically run 28 days typical; 8-16 weeks for extended response.
What are the side effects of ARA-290?
Safe profile in multiple clinical trials. Minimal reported adverse events. Occasional mild injection site reactions. No serious safety concerns identified across diabetes, sarcoidosis, and neuropathy patient populations.
Is ARA-290 legal?
Investigational. Underwent Phase II clinical trials. Not FDA-approved.
What is the half-life of ARA-290?
The half-life of ARA-290 is approximately 24 hours, which determines the once daily dosing schedule.
How do you reconstitute ARA-290?
Add bacteriostatic water to the lyophilized ARA-290 vial. Let the water run down the side — never spray on the powder. Swirl gently. Use our peptide calculator for exact amounts.
Can you stack ARA-290 with other peptides?
Synergizes with BPC-157 for comprehensive tissue repair — ARA-290 handles neuropathic and inflammatory pathways while BPC-157 targets connective tissue and gut healing.
Where can you buy ARA-290?
ARA-290 is available as a research chemical from vetted suppliers with third-party COA testing.
How long does it take ARA-290 to work?
Initial effects may be noticed within 1-2 weeks, with more significant results typically appearing by weeks 4-8 of a 28 days typical; 8-16 weeks for extended response cycle.
What makes ARA-290 unique?
The only EPO-derived peptide that completely decouples tissue protection from red blood cell production — providing nerve regeneration without any hematologic effects.
Complete Guide
ARA-290 : Benefits, Dosage, Side Effects & Research
Related Reading
- ARA-290 Dosage Guide
- ARA-290 Benefits
- ARA-290 Side Effects
- ARA-290 Stacking Guide
- ARA-290 Cycle Guide
- ARA-290 Research
Calculate Your ARA-290 Dose
Use our free peptide dosing calculator to get exact reconstitution math and syringe units for ARA-290.
Open Calculator →Research-Grade Sourcing
If you're going to research ARA-290, source matters. These are the suppliers WolveStack has vetted for purity and third-party testing.
Frequently Asked Questions
What is ARA-290?
ARA-290 (Erythropoietin-derived tissue-protective peptide) is a Innate repair receptor agonist, anti-inflammatory peptide. Synthetic 11-amino acid peptide engineered from the tissue-protective domain of erythropoietin (EPO). It is researched for neuropathic pain relief, inflammation reduction, nerve fiber regeneration, improved autonomic function, metabolic control in diabetes.
What is the recommended ARA-290 dosage?
Common dosages: 2-4 mg daily administered once daily via subcutaneous injection. Cycle length: 28 days typical; 8-16 weeks for extended response. Half-life: approximately 24 hours. Use our peptide calculator for exact reconstitution math.
What are the side effects of ARA-290?
Safe profile in multiple clinical trials. Minimal reported adverse events. Occasional mild injection site reactions. No serious safety concerns identified across diabetes, sarcoidosis, and neuropathy patient populations.
Is ARA-290 safe?
ARA-290 has shown a preliminary safety profile in research. Investigational. Underwent Phase II clinical trials. Not FDA-approved. All research should follow appropriate safety protocols.